Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zeria Of Japan To Buy Tilotts Of Switzerland For $128 Million

This article was originally published in PharmAsia News

Executive Summary

Japan's Zeria Pharma said it plans to buy Tilotts Pharma of Switzerland for just over $128 million. Zeria reportedly made the purchase to expand its drug pipeline and widen its marketing ability abroad. Tilotts is attractive to Zeria because of its Asacol (mesalamine) drug for treating hypersensitive bowel syndrome. The product is considered a good fit with Zeria's gastrointestinal line of drugs. Zeria has been developing and marketing Asacol in Japan for the past five years. The purchase of Tilotts gives the Japanese company rights to sell the drug in 53 countries. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts